On Tuesday it was announced that the company RPG Life Sciences Limited was granted a patent for its novel process of producing Risperidone API (Active Pharmaceutical Ingredient) by the Registrar of Patents, USA.
RPG is a leading producer of pharmaceutical and agrochemical in India their products are exported all over the world including Europe, Latin America, Australia, and South East Asian countries. Â
The granting of a patent for this drug is considered an important breakthrough, and is one of theÂ patents granted in the National Phase of the Patent Cooperation Treaty route (PCT).
The PCT was concluded in 1970, amended in 1979, and modified in 1984 and 2001. It is open to States party to the Paris Convention for the Protection of Industrial Property (1883). The Treaty makes it possible to seek patent protection for an invention simultaneously in each of a large number of countries by filing an “international” patent application. Such an application may be filed by anyone who is a national or resident of a Contracting State, and it may generally beÂ filed with the national patent office of the Contracting State of which the applicant is aÂ national or resident or, at the applicant’s option, with the International Bureau of WIPO in Geneva.
RPG has already been granted a patent for Risperidone in several European countries like the UK, Germany, France, and Switzerland.
Risperidone is in a class of medications called atypical anti-psychotics. It is used to treat symptoms of schizophrenia, a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions. Risperidone works by decreasing abnormal excitement in the brain. The worldwide market for the formulations of Risperidone is estimated to be in excess of US$2bn.
According to RPG, the company’s process of manufacturing Risperidone is eco-friendly and novel, and the process is developed from the basic stage and meets the European Pharmaceutical Standards.